Novacyt S.A. Notice of rescheduled AGM (8669O)
October 05 2023 - 9:15AM
UK Regulatory
TIDMNCYT
RNS Number : 8669O
Novacyt S.A.
05 October 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Notice of rescheduled AGM
AGM to be held in Paris on Thursday 26 October
Paris, France and Eastleigh, UK - 05 October 2023 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that the Company's Annual General
Meeting (AGM), due to take place earlier today, will be rescheduled
and held in person in Paris on Thursday 26 October at 1pm BST/2pm
CEST.
To function as a procedural meeting, the AGM requires a
sufficient number of shareholder votes to constitute a quorum to
ensure the AGM is validly held in accordance with French corporate
law. This threshold has not been met, therefore, in accordance with
Article 19 of Novacyt articles of association, the AGM has been
rescheduled.
The rescheduled AGM will be an open meeting exclusively, held in
The Hilton Hotel, Paris Charles De Gaulle Airport, and will also be
streamed online for those shareholders wishing to join virtually.
Online votes will not be open. The agenda will remain the same as
in the first convening and the AGM will comprise of both ordinary
and extraordinary resolutions.
Shareholders can register to view the AGM via the online meeting
platform by visiting https://novacytagm23.eventcaster.co.uk .
Forms of Proxy already completed and submitted and votes cast by
electronic means for the first AGM remain valid for all meetings
subsequently convened with the same agenda (art. R. 225-77 of the
French commercial code). Further information on voting procedures
and deadlines will follow in due course.
Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
SP Angel Corporate Finance LLP (Nominated
Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Jack
McLaren
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
The acquisition of Yourgene in September 2023 added a
complementary international genomics technology and services
business, focussed on delivering accurate molecular diagnostic and
screening solutions, across reproductive health and precision
medicine. Yourgene's portfolio of in vitro diagnostic products
includes non-invasive prenatal tests (NIPT) for Down's Syndrome and
other genetic disorders, Cystic Fibrosis screening tests, invasive
rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow
its Ranger(R) Technology to deliver dynamic target enrichment.
Novacyt is headquartered in Vélizy in France with offices in the
UK in Stokesley, Eastleigh and Manchester. The Company also has
offices in Taipei (divestment pending), Singapore, the US and
Canada and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth
("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFZMGGZKKGFZM
(END) Dow Jones Newswires
October 05, 2023 09:15 ET (13:15 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024